Willingness to participate in HIV vaccine research in a peri-urban South African community

被引:21
作者
Smit, J [1 ]
Middelkoop, K
Myer, L
Seedat, S
Bekker, LG
Stein, DJ
机构
[1] Univ Stellenbosch, MRC, Unit Anxiety & Stress Disorders, Cape Town, South Africa
[2] Univ Cape Town, Demond Tutu HIV Ctr, ZA-7925 Cape Town, South Africa
[3] Sch Publ Hlth & Family Med, Infect Dis Epidemiol Unit, Cape Town, South Africa
[4] Univ Cape Town, Dept Psychiat, ZA-7925 Cape Town, South Africa
关键词
HIV vaccines; participation; clinical trials; south Africa; HIV prevention;
D O I
10.1258/095646206775809259
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Research on willingness to participate in HIV vaccine trials is important in preparations for HIV vaccine research, but there are few data from sub-Saharan Africa. We interviewed 198 individuals in a peri-urban South African community immediately after enrolment into an HIV vaccine preparedness study on their willingness to participate in hypothetical vaccine trials. Overall 23% of participants (n=46) said that they would be willing to participate in an HIV vaccine trial. Willingness was associated with increasing age, male gender, and increasing knowledge about vaccines generally and HIV vaccines specifically. In multivariate analysis, a 1-unit increase in HIV vaccine knowledge score was associated with a 10-fold increase in willingness to participate (adjusted odds ratio, 10.72, 95% confidence intervals: 4.40-26.12). These results suggest that while willingness to participate in HIV vaccine trials is relatively low in this setting, educational campaigns may have a substantial impact on individuals' willingness to participate in research.
引用
收藏
页码:176 / 179
页数:4
相关论文
共 12 条
[1]  
CHESNEY MA, 1995, J ACQ IMMUN DEF SYND, V9, P30
[2]   Past, present and future of HIV vaccine trials in developing countries [J].
Esparza, J ;
Osmanov, S ;
Pattou-Markovic, C ;
Touré, C ;
Chang, ML ;
Nixon, S .
VACCINE, 2002, 20 (15) :1897-1898
[3]   Candidate HIV/AIDS vaccines: lessons learned from the World's first phase III efficacy trials [J].
Francis, DP ;
Heyward, WL ;
Popovic, V ;
Orozco-Cronin, P ;
Orelind, K ;
Gee, C ;
Hirsch, A ;
Ippolito, T ;
Luck, A ;
Longhi, M ;
Gulati, V ;
Winslow, N ;
Gurwith, M ;
Sinangil, F ;
Berman, PW .
AIDS, 2003, 17 (02) :147-156
[4]  
Grinstead O A, 1995, AIDS, V9 Suppl A, pS245
[5]   Willingness to participate in HIV-1 vaccine trials among young Thai men [J].
Jenkins, RA ;
Torugsa, K ;
Markowitz, LE ;
Mason, CJ ;
Jamroentana, V ;
Brown, AE ;
Nitayaphan, S .
SEXUALLY TRANSMITTED INFECTIONS, 2000, 76 (05) :386-392
[6]  
Koblin BA, 2000, J ACQ IMMUN DEF SYND, V24, P451, DOI 10.1097/00126334-200008150-00010
[7]   Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States [J].
Koblin, BA ;
Heagerty, P ;
Sheon, A ;
Buchbinder, S ;
Celum, C ;
Douglas, JM ;
Gross, M ;
Marmor, M ;
Mayer, K ;
Metzger, D ;
Seage, G .
AIDS, 1998, 12 (07) :785-793
[8]  
McGrath JW, 2001, J ACQ IMMUN DEF SYND, V27, P381, DOI 10.1097/00126334-200108010-00009
[9]   Willingness to participate and enroll in a phase 3 preventive HIV-1 vaccine trial [J].
O'Connell, JM ;
Hogg, RS ;
Chan, K ;
Strathdee, SA ;
McLean, N ;
Martindale, SL ;
Willoughby, B ;
Remis, R .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 31 (05) :521-528
[10]   HIV vaccine acceptance among heterosexual clients of a sexually transmitted diseases clinic [J].
Tello, J ;
Soong, SJ ;
Hunter, B ;
Meriwether, R ;
Hook, EW ;
Mulligan, MJ .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1998, 315 (01) :11-16